Glucose and antidiabetic therapy in temozolomide resistance in glioblastoma

doi:10.5306/wjco.v16.i8.108112

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (25)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-2)

Sum=25

Aug 24, 2025 (publication date) through Aug 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Aug 24, 2025; 16(8): 108112
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.108112

Full Size Figure Download Figure

Figure 1 The basic mechanism of action of temozolomide in the treatment of gliomas. Temozolomide reaches high-grade glioma cells after passing through the blood–brain barrier. The active molecule (MTIC), which methylates DNA bases, splits double-strand DNA, and triggers apoptosis. O6-methylguanine-DNA methyltransferase and other DNA repair pathways are in opposition to MTIC action. MTIC: 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide; TMZ: Temozolomide; MGMT: O6-methylguanine-DNA methyltransferase; BBB: Blood-brain barrier. This figure was created by BioRender.com (Supplementary material).

Citation: Begagić E, Džidić-Krivić A, Bečulić H, Pugonja R, Ljevaković A, Bašić B, Nuhović A, Milanović E, Hadžić S, Bećirović E, Buljubašić L, Bećirović M, Pojskić M. Glucose and antidiabetic therapy in temozolomide resistance in glioblastoma. World J Clin Oncol 2025; 16(8): 108112
URL: https://www.wjgnet.com/2218-4333/full/v16/i8/108112.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i8.108112